
News from bariatricnews.net
Media Bias Ratings
Do you diasgree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top bariatricnews.net News

Novo Nordisk · DenmarkNovo Nordisk on Sunday said full results from two late-stage trials of its experimental weight-loss drug CagriSema show that side effects were mainly mild-to-moderate and other outcome results, including blood sugar levels, were positive. The company had previously announced top-line results for the 68-week studies, which found that CagriSema led to nearly 23% weight loss for overweight or obese adults, while overweight type 2 diabetics lost nearly 16% of their weight. Those results, however, disappointed investors, sending Novo's shares lower. The company last month ousted its CEO Lars Fruergaard Jorgensen.See the Story
Data on Novo Nordisk experimental weight-loss drug show mostly mild side effects
76% Center coverage: 33 sources
New drug lowers blood sugar and increases fat burning without negatively affecting appetite or muscle mass
Nitinotes to initiate US trial of the EndoZip System for endoscopic sleeve gastroplasty
Study identifies setmelanotide as a potential treatment for Obesity Hypoventilation Syndrome
First participant dosed GLORY-OSA trial of mazdutide in China
Levita Magnetics' Magnetic Surgical System gains indication for bariatric and hiatal hernia repair procedures
Surgery Leads to 5 Times Greater Weight Loss Than Ozempic, New Research Reveals
67% Center coverage: 3 sources